Document is current
Any future updates will be listed below
-
Authors
Boll, Lilian Marie https://orcid.org/0000-0001-8355-6263
Vázquez Montes de Oca, Sergio https://orcid.org/0009-0004-0269-8876
Camarena, Marta E. https://orcid.org/0000-0001-9319-6388
Castelo, Robert https://orcid.org/0000-0003-2229-4508
Bellmunt, Joaquim https://orcid.org/0000-0003-2328-3421
Perera-Bel, Júlia https://orcid.org/0000-0002-6809-132X
Albà, M. Mar https://orcid.org/0000-0002-7963-7375
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2019-105595GB, PID2021-122726NB-I00)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FIS PI22/00171)
Generalitat de Catalunya (2021SGR00042)
Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021
- License Information
-
More Information
Article History
Received: 27 April 2024
Accepted: 14 January 2025
First Online: 20 February 2025
Competing interests
: Potential conflicts of interest: J.B. has served in consulting or advisory roles for Astellas Pharma, AstraZeneca/MedImmune, Bristol Myers Squibb, Genentech, Novartis, Pfizer, Pierre Fabre, and the healthcare business of Merck KGaA, Darmstadt, Germany; has received travel and accommodation expenses from Ipsen, Merck & Co., Kenilworth, NJ, and Pfizer; reports patents, royalties, other intellectual property from UpToDate; reports stock and other ownership interests in Rainier Therapeutics; has received honoraria from UpToDate; and has received institutional research funding from Millennium, Pfizer, Sanofi, and the healthcare business of Merck KGaA, Darmstadt, Germany. The remaining authors declare no competing interests.
